An interventional study of Canaloplasty and trabeculotomy with the OMNI system. and iStent inject in Glaucoma, Open-Angle, sponsored by Sight Sciences, Inc.. Terminated at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-27.
Sponsored by Sight Sciences, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. — none open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Sight Sciences, Inc..
Among the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc., this one is the only one that started in 2022, is one of 7 with no phase, and was the 5th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →None of the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. is open now. The open studies under Glaucoma, Open-Angle, anywhere →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2022.
This study's enrollment of 10 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 25 across the 8 interventional studies, 49 across the 2 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sight Sciences, Inc. is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 12 (92%) have results posted.
1 of the studies in Glaucoma, Open-Angle by Sight Sciences, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06991270Sight Sciences, Inc.OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
First, to compare safety and effectiveness outcomes for canaloplasty and trabeculotomy using the OMNI Surgical System to implantation of the iStent inject in lowering intraocular pressure (IOP) in pseudophakic eyes with open angle glaucoma (OAG), and second, to compare safety and effectiveness outcomes for canaloplasty alone (using the OMNI Surgical System)to implantation of the iStent Inject in lowering IOP in pseudophakic eyes with OAG.
A multicenter, prospective, parallel group study planned to randomize 459 subjects to either 1)canaloplasty + trabeculotomy with the OMNI, 2)canaloplasty alone with the OMNI, or 3)iStent inject in an equal allocation ratio (1:1:1); The study includes baseline and terminal (Month 12) washout. Up to 26 centers in the UK and EU were planned to participate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following prior treatments for glaucoma:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequential canaloplasty (up to 360 degrees) and trabeculotomy (up to 360 degrees)
Device: Canaloplasty and trabeculotomy with the OMNI system.
Canaloplasty alone (up to 360 degrees)
Device: Canaloplasty
Implantation of trabecular micro bypass stents as per manufacturer's instructions.
Device: iStent inject
Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy
Ab-interno implantation of iStent inject (2 microstents)
Ab-interno canaloplasty (360 degrees) using the OMNI
Mean Change in Unmedicated DIOP From Baseline at the 12-month Postoperative Examination
Mean change in unmedicated DIOP from baseline at the 12-month postoperative examination is the mean of the difference between the baseline DIOP and the Month 12 DIOP for each subject. Baseline and Month 12 DIOP are measured after appropriate washout of any glaucoma medications.
Time frame: 12 months
| Milestone | Canaloplasty Only With the OMNI Surgical System | Canaloplasty + Trabeculotomy With the OMNI Surgical System | iStent Inject |
|---|---|---|---|
| Started | 5 | 1 | 4 |
| Completed | 0 | 0 | 0 |
| Not completed | 5 | 1 | 4 |
| Withdrew: Study terminated | 5 | 1 | 4 |
Mean change in unmedicated DIOP from baseline at the 12-month postoperative examination is the mean of the difference between the baseline DIOP and the Month 12 DIOP for each subject. Baseline and Month 12 DIOP are measured after appropriate washout of any glaucoma medications.
No measurements were reported for this outcome.
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OMNI-canaloplasty Alone | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| OMNI-canaloplasty + Trabeculotomy | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| iStent Inject | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Event | OMNI-canaloplasty Alone | OMNI-canaloplasty + Trabeculotomy | iStent Inject |
|---|---|---|---|
| COVID-19 infectionRespiratory, thoracic and mediastinal disorders | 1/5 | 1/1 | 0/4 |
| IOP elevationEye disorders | 2/5 | 0/1 | 0/4 |
| Anterior chamber inflammationEye disorders | 1/5 | 0/1 | 0/4 |
| Allergic conjunctivitisEye disorders | 1/5 | 0/1 | 0/4 |
| TendinitisGeneral disorders | 1/5 | 0/1 | 0/4 |
The safety analysis population will contain all subjects for whom either the OMNI (canaloplasty alone), OMNI (canaloplasty AND trabeculotomy), or iStent inject is attempted. The study was terminated early due to a business decision.
| Age, Continuous(years) | OMNI-Canaloplasty Only | OMNI-canaloplasty + Trabeculotomy | iStent Inject | Total |
|---|---|---|---|---|
| Mean | 75.6 ± 3.5 | 71 ± 0 | 74.5 ± 5.1 | 74.7 ± 4.0 |
| Sex: Female, Male(Participants) | OMNI-Canaloplasty Only | OMNI-canaloplasty + Trabeculotomy | iStent Inject | Total |
|---|---|---|---|---|
| Female | 2 | 0 | 3 | 5 |
| Male | 3 | 1 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | OMNI-Canaloplasty Only | OMNI-canaloplasty + Trabeculotomy | iStent Inject | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 1 | 3 |
| Not Hispanic or Latino | 2 | 1 | 3 | 6 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | OMNI-Canaloplasty Only | OMNI-canaloplasty + Trabeculotomy | iStent Inject | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 5 | 1 | 3 | 9 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | OMNI-Canaloplasty Only | OMNI-canaloplasty + Trabeculotomy | iStent Inject | Total |
|---|---|---|---|---|
| United Kingdom | 1 | 0 | 1 | 2 |
| Spain | 4 | 1 | 2 | 7 |
| Poland | 0 | 0 | 1 | 1 |
| Diurnal IOP (DIOP)(mm Hg) | OMNI-Canaloplasty Only | OMNI-canaloplasty + Trabeculotomy | iStent Inject | Total |
|---|---|---|---|---|
| Mean | 29.0 ± 4.4 | 26 ± 0 | 24.3 ± 0.5 | 26.8 ± 3.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2022 to primary completion in Nov 2022, 10 months.
Results were first posted in Oct 2025, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sight Sciences, Inc.